CD34 Antibody (ICO-115)
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-29455
Clone ICO-115 was used by HLDA to establish CD designation.
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human, Rat
Cited:
Human, Rat
Applications
Validated:
ELISA, Flow Cytometry, Immunocytochemistry/ Immunofluorescence
Cited:
Flow Cytometry, Immunocytochemistry/ Immunofluorescence
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # ICO-115
Concentration
0.2 mg/ml
Product Specifications
Immunogen
Blast cells of a chronic myeloid leukemia patient
Localization
Cell surface
Specificity
This antibody recognizes a carbohydrate epitope on a single chain, transmembrane, heavily glycosylated protein of 90-120kDa, which is identified as CD34 (VI international workshop on human differentiation antigens). Its expression is a hallmark for identifying pluripotent hematopoietic stem or progenitor cells. Its expression is gradually lost as lineage committed progenitors differentiate. CD34 is a marker of choice for staining blasts in acute myeloid leukemia. In addition, it is expressed by soft tissue tumors, such as solitary fibrous tumor and gastrointestinal stromal tumor. CD34 expression is also found in vascular endothelium. Additionally, proliferating endothelial cells overexpress this molecule than the non-proliferating endothelial cells. Anti-CD34 labels 85% of angiosarcoma and Kaposis sarcoma, but shows low specificity.
Marker
Hematopoietic Stem Cell & Endothelial Marker
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Description
200ug/ml of antibody purified from Bioreactor Concentrate by Protein A or G. Prepared in 10 mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0 mg/ml. (NBP2-33076)
Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80C.
Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80C.
Scientific Data Images for CD34 Antibody (ICO-115)
Flow Cytometry: CD34 Antibody (ICO-115) [NBP2-29455]
Flow Cytometry: CD34 Antibody (ICO-115) [NBP2-29455] - Analysis using the PE conjugate of NBP2-29455. Surface Staining of CD34 on KG-1 cells using CD34 antibody (red) and isotype control (green) at 5 ul/0.5 ug/10^6 cells. PPI negative cell population was gated for analysis.Flow Cytometry: CD34 Antibody (ICO-115) [NBP2-29455]
Flow Cytometry: CD34 Antibody (ICO-115) [NBP2-29455] - Surface flow cytometric analysis of CD34 on KG-1 cells using CD34 antibody (red) and isotype control (green) at 0.5 ug/10^6 cells.Applications for CD34 Antibody (ICO-115)
Application
Recommended Usage
Flow Cytometry
1-2 ug/million cells
Immunocytochemistry/ Immunofluorescence
1-2 ug/ml
Application Notes
ELISA: For coating, order antibody without BSA).
Optimal dilution for a specific application should be determined.
Optimal dilution for a specific application should be determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Reviewed Applications
Read 1 review rated 5 using NBP2-29455 in the following applications:
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
10 mM PBS with 0.05% BSA
Preservative
0.05% Sodium Azide
Concentration
0.2 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C.
Background: CD34
CD34 has commonly been used as a marker for the diagnosis and classification of various diseases and pathologies including leukemia and solitary fibrous tumor (SFT) (2,5). In terms of immunohistochemistry and histopathology, CD34 has been the most common marker for SFT and is expressed in ~79% of cases (5). In addition to its use as a cell marker, CD34-postive (CD34+) hematopoietic stem cells have been used therapeutically in patients following radiation or chemotherapy due to their regenerative potential (6). There are several clinical trials showing promising results for CD34+ cell therapy for cardiovascular diseases including heart failure, ischemia, dilated cardiomyopathy, acute myocardial infarction, and angina (6). Besides hematopoietic lineages, CD34 is also expressed in non-hematopoietic cells including mesenchymal stem cells, endothelial cells and progenitors, fibrocytes, muscle satellite cells, and some cancer stem cells (1,3). While the clinical and cell therapy applications of CD34 as a cell marker is well documented, the function of CD34 is less understood but has been implicated in many cellular processes such as adhesion, proliferation, signal transduction, differentiation, and progenitor phenotype maintenance (1,3).
References
1. Sidney, L. E., Branch, M. J., Dunphy, S. E., Dua, H. S., & Hopkinson, A. (2014). Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem cells (Dayton, Ohio), 32(6), 1380-1389. https://doi.org/10.1002/stem.1661
2. Krause, D. S., Fackler, M. J., Civin, C. I., & May, W. S. (1996). CD34: structure, biology, and clinical utility. Blood, 87(1), 1-13
3. Kapoor, S., Shenoy, S. P., & Bose, B. (2020). CD34 cells in somatic, regenerative and cancer stem cells: Developmental biology, cell therapy, and omics big data perspective. Journal of cellular biochemistry, 121(5-6), 3058-3069. https://doi.org/10.1002/jcb.29571
4. Uniprot (P28906)
5. Davanzo, B., Emerson, R. E., Lisy, M., Koniaris, L. G., & Kays, J. K. (2018). Solitary fibrous tumor. Translational gastroenterology and hepatology, 3, 94. https://doi.org/10.21037/tgh.2018.11.02
6. Prasad, M., Corban, M. T., Henry, T. D., Dietz, A. B., Lerman, L. O., & Lerman, A. (2020). Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease. Cardiovascular research, 116(8), 1424-1433. https://doi.org/10.1093/cvr/cvaa027
Additional CD34 Products
Product Documents for CD34 Antibody (ICO-115)
Product Specific Notices for CD34 Antibody (ICO-115)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...